ライフサイエンスコーパス: paraganglioma

1 ed primary or metastatic pheochromocytoma or paraganglioma.

2 of primary or metastatic pheochromocytoma or paraganglioma.

3 umor of the carotid body, which was likely a paraganglioma.

4 gene, were found in patients with hereditary paraganglioma.

5 n patients with advanced pheochromocytoma or paraganglioma.

6 rticipants with advanced pheochromocytoma or paraganglioma.

7 cificity in subtypes of pheochromocytoma and paraganglioma.

8 proved for patients with pheochromocytoma or paraganglioma.

9 f-function HIF2 mutations are also linked to paraganglioma.

10 metastatic or inoperable pheochromocytoma or paraganglioma.

11 itical threshold prevents the development of paraganglioma.

12 n neovascularization of pheochromocytoma and paraganglioma.

13 pVHL variants associated with a low risk of paraganglioma.

14 and hemangioblastomas without a high risk of paraganglioma.

15 riers (79%), particularly with head and neck paraganglioma.

16 ontribute to hereditary pheochromocytoma and paraganglioma.

17 with the third recurrence of retroperitoneal paraganglioma.

18 patients with suspected pheochromocytoma or paraganglioma.

19 gulare, 3 glomus tympanicum, and 1 laryngeal paraganglioma.

20 35 right, 1 bilateral); 2 were extra-adrenal paragangliomas.

21 ity with or without associated head and neck paragangliomas.

22 ear cell renal cell carcinomas (ccRCCs), and paragangliomas.

23 als to kidney cancer, hemangioblastomas, and paragangliomas.

24 Pheochromocytomas are adrenal paragangliomas.

25 s like neuroblastoma, pheochromocytomas, and paragangliomas.

26 to three patients harboring glomus jugulare paragangliomas.

27 and tumor size in patients with carotid body paragangliomas.

28 ad a deleterious SDHC mutation, which causes paragangliomas.

29 for known or suspected pheochromocytomas or paragangliomas.

30 e detection and staging of pheochromocytomas/paragangliomas.

31 , and 9 patients with extraadrenal abdominal paraganglioma (1 nonmetastatic, 8 metastatic), underwent

32 ial septal defect (24%), microcephaly (17%), paraganglioma (17%), and ovarian cancer (6.8%).

33 n were carotid paragangliomas (59) and vagal paragangliomas (27).

34 HNP were found; the most common were carotid paragangliomas (59) and vagal paragangliomas (27).

35 t DNMT3A PWWP domain mutations identified in paragangliomas(9) and microcephalic dwarfism(10) promote

36 ate with disease in a family with hereditary paraganglioma, a neuroendocrine tumor previously linked

37 hromocytomas occur and may be referred to as paragangliomas, although this term is also used to descr

38 of primary or metastatic pheochromocytoma or paraganglioma and 69 with suspected pheochromocytoma or

39 well-differentiated, nonfunctional malignant paraganglioma and a 70-y-old male patient with a metasta

40 he germ line of two families with hereditary paraganglioma and is conserved among four eukaryotic mul

41 tivity of (18)F-DOPA PET in the detection of paraganglioma and its metastatic lesions and to evaluate

42 activity was also measured in SDH-deficient paraganglioma and KIT mutant GIST; 4 of 34 patients (12%

43 ere associated with pheochromocytoma but not paraganglioma and occurred in an age group frequently ex

44 enting with paraganglioma and the other with paraganglioma and somatostatinoma, both of whom had poly

45 (HIF2A) in two patients, one presenting with paraganglioma and the other with paraganglioma and somat

46 e in the management of pheochromocytomas and paragangliomas and often guides treatment.

47 ncer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL).

48 Paragangliomas and pheochromocytomas are genetically het

49 ing, and follow-up indicated the presence of paragangliomas and pheochromocytomas in 68 patients and

50 nd a specificity of 88% for the detection of paragangliomas and pheochromocytomas on a patient basis

51 The average (18)F-DOPA uptake by paragangliomas and pheochromocytomas, expressed as a tum

52 imaging essay reviews the characteristics of paragangliomas and the use of multimodality imaging for

53 18)F-flubrobenguane in pheochromocytomas and paragangliomas and to investigate the biodistribution in

54 docrine tumors, especially in neuroblastoma, paraganglioma, and pheochromocytoma.

55 ients, 54 had PPGLs (40 pheochromocytomas, 7 paragangliomas, and 7 metastatic PPGLs), and 21 had non-

56 e have been linked to uterine leiomyomas and paragangliomas, and cancer cells have been shown to indu

57 aragangliomas, with a focus on head and neck paragangliomas, and discusses its impact on the manageme

58 SDHC) cause susceptibility to head and neck paragangliomas, and may be found in approximately 20% of

59 stinal stromal tumors (GISTs), extra-adrenal paragangliomas, and pulmonary chondromas.

60 oendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC),

61 stric GIST; a retroperitoneal, nonfunctional paraganglioma; and a mediastinal, catecholamine-secretin

62 sitivity of (18)F-DOPA PET for metastases of paraganglioma appears to be limited.

63 ost cases of metastatic pheochromocytoma and paraganglioma are driven by dysregulation of the hypoxia

64 Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal m

65 The imaging features of gangliocytic paraganglioma are suggestive enough for the prospective

66 ms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options

67 Pheochromocytomas and paragangliomas are a rare tumor entity originating from

68 Most often, paragangliomas are benign and progress slowly, but metas

69 Paragangliomas are benign neuroendocrine tumors derived

70 Pheochromocytomas and paragangliomas are genetically heterogeneous neural cres

71 More than one-third of all paragangliomas are hereditary, reflecting the strong gen

72 Most cardiac paragangliomas are incidentally detected at echocardiogr

73 Pheochromocytomas and paragangliomas are infrequent, genetically heterogeneous

74 Head and neck paragangliomas are largely related to the pseudohypoxia

75 Paragangliomas are neuroendocrine tumors that derive fro

76 Whereas benign pheochromocytomas and paragangliomas are often successfully cured by surgical

77 Paragangliomas are rare neuroendocrine tumors of extra-a

78 Paragangliomas are rare neuroendocrine tumors that may a

79 Pheochromocytomas and paragangliomas are rare tumors of chromaffin cell origin

80 Carotid body paragangliomas are rare tumors that often affect patient

81 Paragangliomas are typically located around the great ve

82 Paragangliomas arise from the sympathetic or parasympath

83 system, with the majority of parasympathetic paragangliomas arising in the head and neck.

84 A 49-year-old patient with bilateral paragangliomas around branches of carotid arteries.

85 Pheochromocytomas and paragangliomas associated with succinate dehydrogenase (

86 tations in the classic pheochromocytoma- and paraganglioma-associated genes (632 female [65.0%] and 3

87 The tumor was diagnosed as a mediastinal paraganglioma at histologic assessment.

88 The PET/CT findings were grouped as HNPs, paraganglioma at other sites (non-HNPs), and metastatic

89 ts with HNPs and can demonstrate synchronous paragangliomas at other sites and distant metastases.

90 ma and 69 with suspected pheochromocytoma or paraganglioma based on symptoms of catecholamine excess,

91 paradigm in suspected pheochromocytomas and paragangliomas because of its homology with MIBG and the

92 cant difference in the prevalence of carotid paragangliomas between patients with SDHB and SDHD mutat

93 ct can be rescued by pVHL variants linked to paraganglioma, but not by pVHL variants associated with

94 e are tumor suppressor genes predisposing to paraganglioma, but only mutations in the SDHB subunit ar

95 specificity for imaging pheochromocytoma and paraganglioma, but with low sensitivity because of low s

96 metastatic or inoperable pheochromocytoma or paraganglioma by the U.S. Food and Drug Administration h

97 pheochromocytomas and extraadrenal abdominal paragangliomas by increasing the tumor-to-background rat

98 e coronary arteries should be determined, as paragangliomas can be perfused by the coronary arteries,

99 tients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the su

100 Given the lack of human paraganglioma cell lines, we studied the effects of inac

101 n for renal cell carcinoma, pheochromocytoma/paraganglioma, cerebral hemangioblastoma, and endolympha

102 adiopharmaceuticals for pheochromocytoma and paraganglioma (collectively named PPGLs) imaging, severa

103 ether the genotypes of pheochromocytomas and paragangliomas correlate with the uptake of (18)F-DOPA.

104 fter resection in patients with carotid body paragangliomas despite earlier intervention.

105 Paraganglioma develops from cells of the parasympathetic

106 clinically characterize the pheochromocytoma/paraganglioma diseases associated with mutations of the

107 ovide excellent anatomic characterization of paragangliomas, gallium 68 tetraazacyclododecane tetraac

108 The genes responsible for hereditary paragangliomas (glomus tumors, MIM No.

109 GIST without a personal or family history of paraganglioma had germline mutations in SDHB or SDHC.

110 colleagues describe DNA hypermethylation in paragangliomas harboring mutations in succinate dehydrog

111 The molecular basis of paragangliomas has been investigated extensively in the

112 tiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX,

113 etastatic or inoperable pheochromocytoma and paraganglioma, has resulted in renewed interest.

114 almost all VHL disease families that develop paraganglioma have missense VHL mutations.

115 Hereditary head and neck paragangliomas (HNP) are very often associated with pheo

116 ng modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging w

117 ne evaluation of patients with head and neck paragangliomas (HNPs).

118 Histology confirmed pheochromocytoma or paraganglioma in 11 cases (8 adrenal, including 2 malign

119 tection and staging of pheochromocytomas and paragangliomas in different genotypes, including VHL-, S

120 difference in the frequency of head and neck paragangliomas in other locations was found.

121 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127 disease.

122 olic processes seen in pheochromocytomas and paragangliomas, including (131)I/(123)I-metaiodobenzylgu

123 90 individuals with pheochromocytomas and/or paragangliomas, including 898 previously unreported case

124 In most cases, paraganglioma is located around the common carotid arter

125 f adrenal pheochromocytomas and extraadrenal paragangliomas is unknown.

126 to gastrointestinal stromal tumor (GIST) and paraganglioma, is caused by germline mutations in succin

127 s associated with retention of extra-adrenal paraganglioma-like tissues resembling the fetal organ of

128 s with SDHD mutations more often had carotid paragangliomas located on the left side than on the righ

129 Metastatic phaeochromocytomas and paragangliomas (MPPGs) are orphan diseases.

130 toma, embryonal and astrocytic brain tumors, paraganglioma, multiple endocrine neoplasia IIB, and neu

131 Carotid and vagal paragangliomas occurred most often.

132 Pheochromocytomas and paragangliomas often exhibit dysregulation of glucose me

133 tations in patients presenting with multiple paragangliomas or somatostatinomas, and polycythemia.

134 Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and r

135 CBTs was higher than that of jugulotympanic paragangliomas (P = 0.026).

136 PET has been increasingly used in imaging paraganglioma, paralleled by great efforts toward the de

137 Pheochromocytomas and paragangliomas (PCC/PGL) are the solid tumour type most

138 ar characterization of pheochromocytomas and paragangliomas (PCCs/PGLs), a rare tumor type.

139 inoma (HNSC) tumors and Pheochromocytoma and Paraganglioma (PCPG) tumors into distinct groups.

140 = 4), myxoma (n = 3), teratoma (n = 2), and paraganglioma, pericardial cyst, Purkinje cell tumor, an

141 Introduction Pheochromocytoma (PCC) and paraganglioma (PG) research is limited due to rarity of

142 Pheochromocytomas (PC) and paragangliomas (PG) are rare neuroendocrine tumors assoc

143 itary SDHB-mutant pheochromocytomas (PC) and paragangliomas (PG) are rare tumours with a high propens

144 Hereditary paraganglioma (PGL) is characterized by the development

145 ve SDH subunit genes predisposes to familial paraganglioma (PGL) or pheochromocytoma (PHEO).

146 hromosome band 11q23, cause highly penetrant paraganglioma (PGL) tumors when transmitted through fath

147 /= two distinct types of tumors, one of them paraganglioma (PGL), is unusual in an individual patient

148 me complex, succinate dehydrogenase (SDH) in paraganglioma (PGL), it has become clear that some cells

149 dehydrogenase (SDHB) predispose to malignant paraganglioma (PGL).

150 ts with metastatic pheochromocytoma (PC) and paraganglioma (PGL).

151 mical hallmark of pheochromocytoma (PCC) and paraganglioma (PGL).

152 Hereditary nonchromaffin paragangliomas (PGL; glomus tumors; MIM 168000) are most

153 aps within the critical region of hereditary paraganglioma (PGL1) on chromosomal band 11q23, we chara

154 signatures in pheochromocytomas (PHEOs) and paragangliomas (PGLs).

155 with metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs).

156 and metastatic pheochromocytomas (PHEOs) and paragangliomas (PGLs).

157 on monocytes isolated from pheochromocytoma/paraganglioma (PHEO) patients.

158 ; and a mediastinal, catecholamine-secreting paraganglioma (pheochromocytoma).

159 the parasympathetic and sympathetic system (paragangliomas, pheochromocytoma) and other very rare lo

160 fractory stage 4 neuroblastoma or metastatic paraganglioma/pheochromocytoma (MP) were treated using a

161 MIBG has essentially been only palliative in paraganglioma/pheochromocytoma patients.

162 en patients (5 with neuroblastoma and 5 with paraganglioma/pheochromocytoma) received 148-444 MBq (4-

163 euroendocrine tumors, such as neuroblastoma, paraganglioma/pheochromocytoma, and carcinoids; and disc

164 Patients with paragangliomas, pheochromocytomas and neuroblastomas wer

165 ighly sensitive method for pheochromocytomas/paragangliomas (PHEOs/PGLs) associated with succinate de

166 atients with pheochromocytoma or sympathetic paraganglioma (PPGL) develop metastatic disease, most of

167 unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatme

168 Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythe

169 Pheochromocytoma and Paraganglioma (PPGL) tumours with known genetic aetiolog

170 reditary tumors such as pheochromocytoma and paraganglioma (PPGL), renal cell carcinoma, and gastroin

171 oses to the development of phaeochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal

172 f the genetic basis of phaeochromocytoma and paraganglioma (PPGL).

173 uation of patients with pheochromocytoma and paraganglioma (PPGL).

174 Phaeochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumours th

175 Pheochromocytomas and paragangliomas (PPGLs) can be localized by (18)F-FDG PET

176 Pheochromocytomas and paragangliomas (PPGLs) present diagnostic challenges due

177 Pheochromocytomas and paragangliomas (PPGLs) provide some of the clearest gene

178 se for treating metastatic pheochromocytomas/paragangliomas (PPGLs), a rare SSTR-expressing tumor.

179 current or metastatic phaeochromocytomas and paragangliomas (PPGLs).

180 al characterization of pheochromocytomas and paragangliomas (PPGLs).

181 Paragangliomas rarely involve the heart, and they accoun

182 alignant pheochromocytoma, neuroblastoma, or paraganglioma receiving [(131)I]MIBG treatment, as well

183 up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence of SDHA, TMEM127,

184 yndrome in some circumstances and to cancer (paraganglioma, renal cell carcinoma, gastrointestinal st

185 r patients underwent 41 primary carotid body paraganglioma resections (median follow-up time of 42 mo

186 y identified as a novel pheochromocytoma and paraganglioma susceptibility gene.

187 N 2), the newly delineated phaeochromocytoma-paraganglioma syndrome and, less commonly, neurofibromat

188 enase subunits SDHB-D cause pheochromocytoma-paraganglioma syndrome.

189 very often associated with pheochromocytoma-paraganglioma syndromes, which are caused by mutations i

190 e endocrine neoplasia-2 (MEN2), and familial paraganglioma syndromes.

191 mean) was seen for both pheochromocytoma and paraganglioma than for healthy adrenal glands (11.9 +/-

192 mean) was seen for both pheochromocytoma and paraganglioma than for healthy adrenal glands (11.9 2.0

193 y advanced or metastatic pheochromocytoma or paraganglioma that was not amenable to surgery or curati

194 in a patient with polycythemia and multiple paragangliomas (the Pacak-Zhuang syndrome).

195 ing is now recommended for all patients with paragangliomas to provide screening and surveillance rec

196 enetic mutations alter the aggressiveness of paragangliomas, treatment decisions are currently based

197 nate dehydrogenase; SDH) genes predispose to paraganglioma tumors that show constitutive activation o

198 adrenal (pheochromocytoma) and extraadrenal (paraganglioma) tumors, sensitivities were 88% and 67%, r

199 At MRI, cardiac paragangliomas typically have low to intermediate signal

200 patients with suspected pheochromocytoma or paraganglioma underwent PET/CT or PET/MRI at 63 +/- 24 m

201 patients with suspected pheochromocytoma or paraganglioma underwent PET/CT or PET/MRI at 63 24 min a

202 t-Hogg-Dube Syndrome, Carcinoma, Renal Cell, Paragangliomas, Urinary, Kidney (C) RSNA, 2024.

203 utation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT.

204 gs in five patients with proved gangliocytic paraganglioma were reviewed.

205 GIST without a personal or family history of paraganglioma were tested for SDH germline mutations.

206 ing approaches used in pheochromocytomas and paragangliomas, which vary among clinical and genotypic

207 of patients with metastatic pheochromocytoma/paraganglioma who presented with a primary tumor in chil

208 modialysis-dependent patient with metastatic paraganglioma who was treated with [(131)I]MIBG.

209 ve analysis of 34 patients with carotid body paragangliomas who underwent genetic testing and surgica

210 colon cancer, 1 lung cancer, and 1 malignant paraganglioma) who underwent separate (18)F PET/CT and (

211 discuss the therapy of pheochromocytoma and paraganglioma with (131)I-MIBG and (90)Y- or (177)Lu-DOT

212 radionuclide therapy of pheochromocytoma and paraganglioma with (90)Y- or (177)Lu-DOTA conjugated som

213 who present with metastatic pheochromocytoma/paraganglioma with primary tumor development in childhoo

214 -line imaging in patients with head and neck paragangliomas with concern for multifocal and metastati

215 e introduces the molecular classification of paragangliomas, with a focus on head and neck paragangli